MFC Co

MFC Co EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of MFC Co (432980.KQ) as of Oct 28, 2026 is 8.49. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 3,525.73 — a change of -99.76% (lower).

EV/OCF

8.49

YoY

-99.76%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of MFC Co is 2024 8.49 . EV/OCF (Enterprise Value to Operating Cash Flow) of MFC Co was 2023 3,525.73 . It decreases by -99.76% lower compared to the previous year.

The MFC Co EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2022
76.60 KRW
Jan 1, 2023
3,525.73 KRW
Jan 1, 2024
8.49 KRW
The MFC Co EV/OCF history
YEAREV/OCFYoY
8.49-99.76%
3,525.73+4,502.92%
76.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MFC Co Stock analysis

What does MFC Co do? MFC Co Ltd generates revenue primarily through the development and production of active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials for the pharmaceutical industry. The company focuses on creating basic pharmaceutical substances and raw material pharmaceuticals, serving clients in the pharmaceutical sector. Its products are sold to pharmaceutical manufacturers who require these materials for drug formulation. The company operates within the pharmaceutical research and development segment, targeting firms involved in drug production and formulation. MFC Co Ltd's business model centers on providing essential raw materials and intermediates to pharmaceutical companies. By specializing in API, KSM, and intermediate materials, the company supports the manufacturing processes of its clients. The firm's revenue streams are derived from the sale of these specialized pharmaceutical components to manufacturers who integrate them into their final drug products. The company's target market consists of pharmaceutical manufacturers requiring high-quality raw materials for their production lines. The company's core offerings include active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials, which are critical for pharmaceutical manufacturing. These products are sold to pharmaceutical manufacturers as part of their supply chain. MFC Co Ltd's revenue is generated through the direct sale of these materials to clients in the pharmaceutical industry. The company's focus on R&D for pharmaceutical substances ensures a steady demand for its products from drug manufacturers seeking reliable suppliers. MFC Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MFC Co stock

EV/OCF (Enterprise Value to Operating Cash Flow) of MFC Co is 8.49 in 2024.

EV/OCF (Enterprise Value to Operating Cash Flow) of MFC Co changed from 3,525.73 to 8.49, representing a -99.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) MFC Co since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s MFC Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — MFC Co

All Key Metrics — MFC Co